Entrepreneurial Accelerator Program (EAP) Portfolio Company receives $400,000 Research Grant from The National Cancer Institute to study a repurposed drug in treatment of Glioblastoma
Oleolive, Inc., awarded a $400,000 STTR Phase 1 grant, researches Propentofylline (PPF) for Glioblastoma Multiforme (GBM) treatment. PPF, a repurposed drug, aims to enhance GBM tumor cells' chemosensitivity, potentially improving patient survival beyond the current 1.25-year average. Oleolive, a preclinical biotech company, focuses on treating brain cancer, Alzheimer's, and other conditions.
Reference News
Oleolive, Inc., awarded a $400,000 STTR Phase 1 grant, researches Propentofylline (PPF) for Glioblastoma Multiforme (GBM) treatment. PPF, a repurposed drug, aims to enhance GBM tumor cells' chemosensitivity, potentially improving patient survival beyond the current 1.25-year average. Oleolive, a preclinical biotech company, focuses on treating brain cancer, Alzheimer's, and other conditions.